title: Role of the superior colliculus in the motor effects of cannabinoids and dopamine.
abstract: We studied the cellular distribution of CB1 cannabinoid receptors in the superior colliculus of the rat using an antibody raised against the N-terminal of the receptor. The effect of unilateral cannabinoid receptor stimulation in the intermediate layers of the superior colliculus on rotational behavior in rats was also explored. The antibody against CB1 receptors outlined the crossed descending system of the superior colliculus (predorsal bundle output system) as well as the collicular commisure. The potent cannabinoid agonist CP55,940 (5 microgram/0.25 microliter) induced strong contralateral turning when microinjected unilaterally into the lateral intermediate layers of the superior colliculus. The levels of turning obtained with the intracollicular administration of the cannabinoid were comparable to the highest levels obtained with dopamine agonists in the basal ganglia. The D(2) dopamine agonist quinpirole or the D(1) dopamine agonist SKF82958 reversed this contralateral rotation but failed to affect motor behavior on their own. A new motor pathway for cannabinoids is discussed.
authors.affiliation: Schrier Research Laboratory, Department of Psychology, Brown University, 89 Waterman Street, Providence, RI, USA. clara@quasar.psych.brown.edu
authors.forename: M C
authors.initials: MC
authors.lastname: Sañudo-Peña
authors.forename: K
authors.initials: K
authors.lastname: Tsou
authors.forename: J
authors.initials: J
authors.lastname: Romero
authors.forename: K
authors.initials: K
authors.lastname: Mackie
authors.forename: J M
authors.initials: JM
authors.lastname: Walker
mesh_terms: D000700:Analgesics / Q000008:administration & dosage; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001552:Benzazepines / Q000008:administration & dosage; D002186:Cannabinoids / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D003511:Cyclohexanols / Q000008:administration & dosage; D004298:Dopamine / Q000378:metabolism*; D018491:Dopamine Agonists / Q000008:administration & dosage; D008297:Male; D008845:Microinjections; D009043:Motor Activity / Q000187:drug effects*; D051381:Rats; D017207:Rats, Sprague-Dawley; D043882:Receptors, Cannabinoid; D017447:Receptors, Dopamine D1 / Q000819:agonists / Q000378:metabolism; D017448:Receptors, Dopamine D2 / Q000819:agonists / Q000378:metabolism; D011955:Receptors, Drug / Q000378:metabolism*; D013477:Superior Colliculi / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism*
chemical_list: D000700:Analgesics; D001552:Benzazepines; D002186:Cannabinoids; D003511:Cyclohexanols; D018491:Dopamine Agonists; D043882:Receptors, Cannabinoid; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D011955:Receptors, Drug; C071262:SK&F 82958; C054649:3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol; D004298:Dopamine